MaxCyte Inc on Monday celebrated the signing of a strategic platform license agreement with Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company.
MaxCyte is a Rockville, Maryland-based provider of cell engineering platform technologies.
According to the terms of the deal, Kamau gets non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform.
In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
‘Bringing this groundbreaking gene therapy research into the clinic requires a robust manufacturing process and the ability to scale,’ said Chief Executive Officer Maher Masoud.
‘By partnering with us, Kamau gains access to our commercially validated Flow Electroporation technology as well as technical, regulatory and scientific support. This enables them to optimize their clinical manufacturing process, mitigate risks and expedite the progression of their lead product candidate through clinical phases to deliver this potential cure to patients living with SCD.’
Shares in MaxCyte were trading 2.9% higher at 308.60 pence each in London on Monday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
